Aktie 4147 TAIMED BIOLOGICS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen TaiMed Biologics Inc.

Aktien

4147

TW0004147004

4147

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 30.04.2024 		% 5 Tage % 1. Jan.
85.5 TWD -0.58% Intraday Chart für TaiMed Biologics Inc. +4.52% +4.27%
20.03. TaiMed Biologics Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
13.03. Taimed Biologics und AcedrA Biopharmaceticals kooperieren bei der Vermarktung von Trogarzo in der Region Naher Osten und Nordafrika CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
US FDA Approves the Supplemental Biologicslicense Application for Intravenous (IV) Pushadministration of Trogarzo
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
TaiMed Biologics : First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 4147 Aktie
  4. Nachrichten TaiMed Biologics Inc.
  5. Andere Sprachen